Literature DB >> 6376061

Controlled-release delivery systems for hormones. A review of their properties and current therapeutic use.

L R Beck, V Z Pope.   

Abstract

Biomedical engineering approaches used to develop controlled-release delivery systems for hormones are here reviewed regarding system design and therapeutic applications. The biomedical engineering approach uses a system of non-drug components to control the rate and duration of hormone delivery. The non-drug components vary from system to system, but generally include: a reservoir for the hormone; a barrier or regulator to contain the hormone within the reservoir and to control its release; an energy source to remove the hormone from the reservoir; and a pathway for egress of the hormone from the system. Controlled-release delivery systems for hormones discussed in this review include mechanical and osmotic pumps; intraocular, intravaginal and intrauterine platform devices; biodegradable and non-biodegradable subcutaneous implants; and small particulate systems including microcapsules, microspheres and liposomes. Examples of the therapeutic application of the various systems are given along with a discussion of design factors and pharmacological aspects relevant to their clinical use.

Mesh:

Substances:

Year:  1984        PMID: 6376061     DOI: 10.2165/00003495-198427060-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  74 in total

1.  A D-norgestrel-releasing IUD.

Authors:  C G Nilsson; E D Johansson; T Luukkainen
Journal:  Contraception       Date:  1976-04       Impact factor: 3.375

2.  A permanently implantable self-recycling low flow constant rate multipurpose infusion pump of simple design.

Authors:  P J Blackshear; F D Dorman; P L Blackshear; R L Varco; H Buchwald
Journal:  Surg Forum       Date:  1970

3.  Preclinical evaluation of intrauterine progesterone as a contraceptive agent. II. Possible mechanisms of action.

Authors:  S A Tillson; R Hudson; D Swisher; P Leong
Journal:  Contraception       Date:  1978-05       Impact factor: 3.375

4.  Endometrial morphology in women exposed to uterine systems releasing progesterone.

Authors:  J Martínez-Manautou; M Maqueo; R Aznar; B B Pharriss; A Zaffaroni
Journal:  Am J Obstet Gynecol       Date:  1975-01-15       Impact factor: 8.661

5.  Comparison of selected intravenous infusion pumps and rate regulators.

Authors:  J G Kitrenos; M Jones; D C McLeod
Journal:  Am J Hosp Pharm       Date:  1978-03

6.  Measurement of medroxyprogesterone acetate (Provera ) by radioimmunoassay.

Authors:  J C Cornette; K T Kirton; G W Duncan
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

7.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti
Journal:  Br Med J       Date:  1978-01-28

8.  Ovulation induction with luteinizing hormone--releasing hormone in amenorrheic, infertile women.

Authors:  C B Hammond; R H Wiebe; A F Haney; S G Yancy
Journal:  Am J Obstet Gynecol       Date:  1979-12-01       Impact factor: 8.661

9.  Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.

Authors:  W F Crowley; F Comite; W Vale; J Rivier; D L Loriaux; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

10.  Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.

Authors:  F Alvarez; V Brache; A Faundes; E D Johansson; V Odlind; H Nash
Journal:  Contraception       Date:  1983-02       Impact factor: 3.375

View more
  4 in total

1.  Sustained release of a corticosteroid using polymeric implants.

Authors:  S Cawley; D J Ormrod; J W Paxton; T E Miller
Journal:  Agents Actions       Date:  1986-11

Review 2.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

3.  Formulation and performance characterization of radio-sterilized "progestin-only" microparticles intended for contraception.

Authors:  Shivanand Puthli; Pradeep Vavia
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

4.  Osteogenic differentiation of follicular stem cells on nano-Saghez scaffold containing BMP2.

Authors:  Hananeh Bayat; Hassan Shahabinejad; Mohammad Bayat; Sadegh Shirian; Abdolreza Mohamadnia; Mohammadreza Alijani; Arash Godarzi; Pegah Shojaei; Sahar Shojaei; Abolfazl Shevidi; Naghmeh Bahrami
Journal:  J Orthop Surg Res       Date:  2019-12-16       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.